BIOE (Bio Essence) Asset Turnover: 0.83 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOE Bio Essence Corp BIOE
31 GF Score
Price $0.27
! 4 Warning Signs
View Full Analysis

What is Bio Essence Asset Turnover?

Bio Essence BIOE 31 Asset Turnover is 0.83 as of Mar. 2026. GuruFocus rates BIOE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Bio Essence's Revenue for the three months ended in Mar. 2026 was $0.50 Mil. Bio Essence's Total Assets for the quarter that ended in Mar. 2026 was $0.61 Mil. Therefore, Bio Essence's Asset Turnover for the quarter that ended in Mar. 2026 was 0.83.

Asset Turnover is linked to ROE % through Du Pont Formula. Bio Essence's annualized ROE % for the quarter that ended in Mar. 2026 was -46.84%. It is also linked to ROA % through Du Pont Formula. Bio Essence's annualized ROA % for the quarter that ended in Mar. 2026 was 135.43%.


Bio Essence  (OTCPK:BIOE) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Bio Essence's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=0.82/-1.7505
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0.82 / 2.004)*(2.004 / 0.6055)*(0.6055/ -1.7505)
=Net Margin %*Asset Turnover*Equity Multiplier
=40.92 %*3.3097*-0.3459
=ROA %*Equity Multiplier
=135.43 %*-0.3459
=-46.84 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Bio Essence's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=0.82/0.6055
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0.82 / 2.004)*(2.004 / 0.6055)
=Net Margin %*Asset Turnover
=40.92 %*3.3097
=135.43 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Bio Essence Asset Turnover Related Terms


Bio Essence Asset Turnover Historical Data

* Premium members only.

The historical data trend for Bio Essence's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio Essence Asset Turnover Chart

Bio Essence Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial 0.50 0.38 0.00 0.21 5.40

Bio Essence Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 1.08 0.92 4.87 0.83

BIOE vs BFRI, APUS, CABR: Asset Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio Essence Asset Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bio Essence's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Bio Essence's Asset Turnover falls into.


BIOE
31GF Score
Bio Essence Corp BIOE
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio Essence Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Bio Essence's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=1.898/( (0.281+0.422)/ 2 )
=1.898/0.3515
=5.40

Bio Essence's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0.501/( (0.422+0.789)/ 2 )
=0.501/0.6055
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.83 mean?
Bio Essence (BIOE) has a Asset Turnover of 0.83 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Bio Essence and its competitors.
Is Bio Essence's Asset Turnover too high?
Bio Essence's current Asset Turnover is 0.83. Overall, Bio Essence has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's Asset Turnover compare to BFRI and APUS?
Bio Essence's Asset Turnover of 0.83 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Drug Manufacturers company?
A good Asset Turnover depends on the Drug Manufacturers industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Bio Essence and its competitors. Bio Essence's current Asset Turnover is 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current Asset Turnover of 0.83. The current Asset Turnover is 0.83. Bio Essence's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Bio Essence (BIOE), the current Asset Turnover is 0.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio Essence Business Description

Address 2955 Main Street, Suite 300, Irvine, CA, USA, 92618
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
31GF Score

Get the complete analysis for BIOE

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.27
Price